HomeAI · summaries
Storia in 8 fonti
Lilly shares safety, tolerability data on its next-gen obesity drug
Eli Lilly presented new safety and tolerability data on retatrutide at the annual meeting of the American Diabetes Association on Saturday.
Confronto fonti
6 prospettive sulla stessa storiaTimeline cronologica
- ·
healio.com
Retatrutide benefits in obesity, type 2 diabetes ‘quite staggering’
NEW ORLEANS —A triple receptor agonist provided weight loss for adults with obesity, with or without type 2 diabetes, to an extent not seen with previous pharmacotherapy options,…
- ·
morningstar.com
Lilly's triple agonist, retatrutide, drove substantial improvements in weight, A1C, knee osteoarthritis pain, and obstructive sleep apnea,…
Lilly's triple agonist, retatrutide, drove substantial improvements in weight, A1C, knee osteoarthritis pain, and obstructive sleep apnea, demonstrating its remarkable potential…
- ·
statnews.com
Lilly shares safety, tolerability data on its next-gen obesity drug
Eli Lilly presented new safety and tolerability data on retatrutide at the annual meeting of the American Diabetes Association on Saturday.
- ·
economictimes.indiatimes.com
Eli Lilly says next-gen obesity drug curbs sleep apnea, among other benefits
Eli Lilly presented trial results for its new obesity drug retatrutide. The drug significantly reduced sleep apnea severity and knee osteoarthritis pain in adults with obesity.…
- ·
newsbytesapp.com
Eli Lilly's obesity drug shows promise in treating sleep apnea
Eli Lilly's retatrutide significantly reduces sleep apnea severity, knee osteoarthritis pain, and promotes substantial weight loss in adults with obesity, trial results reveal.
- ·
markets.businessinsider.com
Eli Lilly’s (LLY) New Drug Gives Investors a Wake-Up Call as Data Bolsters the Stock’s Growth Story
Eli Lilly and Company (LLY) gave investors another reason to watch its obesity pipeline after new late-stage data showed that its experimental d...
- ·
New data may cast doubt on competitiveness of Boehringer’s obesity drug
Boehringer Ingelheim’s obesity drug showed promise in cutting liver fat, but it was less impressive at overall weight loss, new data shows.
- ·
Competition for obesity drugs, clinical blind spots, and more news from ADA
You're reading the web edition of STAT's ADA in 30 Seconds, from the American Diabetes Association's annual conference.
- ·
biopharmadive.com
ADA ‘26: Lilly’s dominance, Pfizer’s ‘foundational’ drug and Roche’s ‘me-too’ option
At a big meeting for weight loss drugs, Lilly’s “triple G” therapy set a new standard as lingering doubts surrounded other competing treatments.
- ·
Pharmalittle: We're reading about Lilly and Pfizer obesity drug data, Roche and J&J deals, and more
Lilly disclosed new data that provide more details on the safety and tolerability of its next-generation obesity drug retatrutide
- ·
US stocks: Lilly shares rise on hopes that next-gen drug will extend lead in weight-loss market
Lilly presented full data from two retatrutide trials, one in treatment naive type 2 diabetes patients and another in patients with obesity, at the American Diabetes…
- ·
fiercepharma.com
With ADA in the books, analyst says Lilly is ‘widening its lead’ in the obesity race
It’s a sign of the times that this year’s American Diabetes Association (ADA) Scientific Sessions meeting in New Orleans featured more chatter on obesity drugs and pipeline…
- ·
ADA: Lilly posts oral semaglutide-topping data as Foundayo speeds toward 2nd potential nod in diabetes
With an obesity green light already in hand, Eli Lilly is pushing for its newly launched Foundayo (orforglipron) to break into Type 2 diabetes, in turn rounding out its oral…